Preferred Label : mTORC 1/2 Inhibitor LXI-15029;
NCIt related terms : MTI-31;
NCIt definition : An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex
1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with
potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029
binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive
manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis
and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a
serine/threonine kinase that is upregulated in certain tumor cell types. It plays
an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated
in cancer cells and promotes cell growth, survival, and resistance to chemotherapy
and radiotherapy.;
UNII : RM15YYQ1CI;
CAS number : 1567915-38-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1567915-38-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : LXI-15029; SCC-31; MTI-31;
NCI Metathesaurus CUI : CL551141;
Origin ID : C148528;
UMLS CUI : C4725103;
Semantic type(s)
- concept_is_in_subset
